Oxford Asset Management’s Autolus Therapeutics AUTL Stock Holding History

Oxford Asset Management’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-14,373	Closed	-$190K	–	310
2019 Q4	$190K	Buy	+14,373	New	+$188K	0.01%	1559
2019 Q1	–	Sell	-48,672	Closed	-$1.6M	–	1654
2018 Q4	$1.6M	Sell	48,672 -28,698	-37%	-$944K	0.04%	595
2018 Q3	$2.35M	Sell	77,370 -39,950	-34%	-$1.08M	0.05%	572
2018 Q2	$3.04M	Buy	+117,320	New	+$3.1M	0.06%	405

Other funds holding AUTL

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Oxford Asset Management's AUTL Position: Q1 2020 in Review

Oxford Asset Management sold out of Autolus Therapeutics (AUTL) in Q1 2020, closing a stake of 14,373 shares — an estimated $190K sold.

Oxford Asset Management first reported a position in AUTL in Q2 2018 and held it in 4 quarters. The position peaked at $3.04M in Q2 2018. 51 funds tracked by Wall St. Rank hold AUTL as of Q1 2020.

Oxford Asset Management reported no remaining Autolus Therapeutics position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 14,373 Autolus Therapeutics shares in Q1 2020, an estimated $190K.
Oxford Asset Management first reported a position in Autolus Therapeutics in Q2 2018 and held it in 4 quarters.
Oxford Asset Management's Autolus Therapeutics position peaked at $3.04M in Q2 2018.
51 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.